Aligos Therapeutics/ALGS

$0.79

-0.33%
-
1D1W1MYTD1YMAX

About Aligos Therapeutics

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases. The Company discovers and develops therapeutics for metabolic dysfunction associated steatohepatitis (MASH) and viruses with high unmet medical need, such as chronic hepatitis B (CHB) and coronaviruses. Its advanced drug candidate for MASH is ALG-055009, a small molecule thyroid hormone receptor beta (THR-ß) agonist. It is also progressing oligonucleotide projects for MASH. It is developing a portfolio of differentiated CHB drug candidates, including a small molecule Capsid Assembly Modulator that results in the production of empty viral capsids (CAM-E) and small molecule inhibitors of the Programmed Cell Death Ligand 1 (PD-1/PD-L1) interaction. Its third area of focus is to develop drug candidates with pan-coronavirus antiviral activity. Its pipeline includes ALG-055009, ALG-000184, ALG-125755, and ALG-097558.

Ticker

ALGS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Lawrence Blatt

Employees

66

Headquarters

South san francisco, United States

ALGS Metrics

BasicAdvanced
$59.55M
Market cap
-
P/E ratio
-$1.82
EPS
2.36
Beta
-
Dividend rate
$59.55M
2.36019
$1.38
$0.54
388.9K
5.902
0.251
0.262
-58.8%
-89.48%
-72.71%
3.835
0.647
0.647
11.66%
19.21%

What the Analysts think about ALGS

Analyst Ratings

Majority rating from 2 analysts.
Buy

Price Targets

Average projection from 2 analysts.
406.33% upside
High $7.00
Low $1.00
$0.79
Current price
$4.00
Average price target

ALGS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,069.23% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$2.6M
-18.75%
Net income
$-27.8M
54.44%
Profit margin
-1,069.23%
90.09%

ALGS Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 18.52%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.53
-$0.43
-$0.41
-$0.22
-
Expected
-$0.49
-$0.50
-$0.48
-$0.27
-$0.19
Surprise
9.28%
-13.13%
-13.68%
-18.52%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Aligos Therapeutics stock?

Aligos Therapeutics (ALGS) has a market cap of $59.55M as of April 20, 2024.

What is the P/E ratio for Aligos Therapeutics stock?

The price to earnings (P/E) ratio for Aligos Therapeutics (ALGS) stock is 0 as of April 20, 2024.

Does Aligos Therapeutics stock pay dividends?

No, Aligos Therapeutics (ALGS) stock does not pay dividends to its shareholders as of April 20, 2024.

When is the next Aligos Therapeutics dividend payment date?

Aligos Therapeutics (ALGS) stock does not pay dividends to its shareholders.

What is the beta indicator for Aligos Therapeutics?

Aligos Therapeutics (ALGS) has a beta rating of 2.36. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Aligos Therapeutics stock price target?

The target price for Aligos Therapeutics (ALGS) stock is $4, which is 433.33% above the current price of $0.75. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Aligos Therapeutics stock

Buy or sell Aligos Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing